
News|Articles|October 19, 2012
FDA warns of serious blood disorder resulting from abuse of Opana ER
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablet (Opana ER, Endo).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























